Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
China
Peking University First Hospital, Beijing, Beijing Municipality Peking University People's Hospital, Beijing, Beijing Municipality Hunan Cancer Hospital, Changsha, Hunan